Murali Chebrolu

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Novartis Ag. Active years: 2014-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Murali Chebrolu. Retrieved from https://idiyas.com/inventor/murali-chebrolu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 85.7

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 9.8

ph-index = 3

Forward Citations = 94(Granted Patents)

Company Filing History:

7 out of 3,975

Novartis Ag

patents

Years Active: 2014-2020

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10683287 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2020-06-16),

2. 10301296 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2019-05-28),

3. 10035794 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2018-07-31),

4. 9550758 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2017-01-24),

5. 8865712 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2014-10-21),

6. 8742106 - Disubstituted heteroaryl-fused pyridines (2014-06-03),

7. 8637508 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2014-01-28),

Title: Murali Chebrolu: Innovator in Neurological Treatments

Introduction

Murali Chebrolu is a prominent inventor based in Andhra Pradesh, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for neurological disorders. With a total of seven patents to his name, Chebrolu's work is recognized for its potential impact on medical science.

Latest Patents

Among his latest patents, Chebrolu has developed novel heterocyclic derivatives aimed at treating neurological disorders. These compounds are designed to serve as medicaments, particularly for conditions such as Alzheimer's Disease and diabetes. The inventions focus on the inhibition of BACE-1 or BACE-2, which are critical in the progression of these diseases. The pharmaceutical compositions and combinations derived from these compounds hold promise for advancing treatment options.

Career Highlights

Chebrolu is currently associated with Novartis AG, a leading global healthcare company. His role involves extensive research and development in the pharmaceutical sector, where he applies his expertise to innovate new therapeutic solutions. His work has garnered attention for its scientific rigor and potential clinical applications.

Collaborations

Some of his notable coworkers include Sangamesh Badiger and Konstanze Hurth. Their collaborative efforts contribute to the advancement of research and development in the field of pharmaceuticals.

Conclusion

Murali Chebrolu's contributions to the field of neurological treatments through his innovative patents highlight his role as a key figure in pharmaceutical research. His work continues to pave the way for new therapeutic options that could significantly improve patient outcomes.

Profile summary based on public USPTO records.